J&J Expects Revenue Growth Despite Stelara Biosimilars, IRA Impact

 
• By Joseph Haas
  
J&J predicts 2025 revenue growth despite the impact of Stelara biosimilars • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Strategy